Meningioma Clinical Trials

Meningioma clinical trials provide valuable information about how to diagnose, treat, prevent and ultimately cure these complex tumors. Most of these studies are designed to compare two or more treatments: the best option currently available and a novel therapy that has the potential to produce better survival outcomes and quality of life, or cause fewer side effects. Other trials are designed to learn more about how or why the condition develops, determine how to reduce the likelihood of recurrence or study new options for screening and prevention.

Some of the most recent clinical trials for meningioma have evaluated:

  • What role chemotherapy can play in meningioma treatment and which chemo medications are most effective
  • How tumor markers can help predict which patients will respond most favorably to specific treatments
  • Whether carbon ion-based treatments can be more effective than traditional postoperative radiation
  • Various options for addressing chronic, meningioma-induced neurological defects and cognitive impairment

At Moffitt Cancer Center, our clinical trials program has contributed to many key developments in brain cancer research. In fact, today’s most effective meningioma treatments were once only available through clinical trials – and a number of those trials took place at Moffitt. Through our clinical research program, patients have unique opportunities to access the latest therapies before those options are available in other settings, and opportunities continue to open up as our researchers steadily work toward finding a brain cancer cure.

For more information about our meningioma clinical trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. No referral is necessary to make an appointment.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18752

ACTION Trial- Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)

Disease Site: Brain and Nervous System, Gliomas

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas

View Trial Details

CLINICAL TRIAL 20110

GBM Agile: Global Adaptive Trial Master Protocol

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 20145

A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 using Convection-enhanced Delivery in Patients with Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection

Disease Site: Brain and Nervous System, Gliomas

View Trial Details

CLINICAL TRIAL 20637

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Disease Site: Brain and Nervous System, Brain metastasis

View Trial Details

CLINICAL TRIAL 20899

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Disease Site: Brain and Nervous System, Breast

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas

View Trial Details

CLINICAL TRIAL 20964

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21022

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Disease Site: Any Site, Brain and Nervous System, Lung, Pancreas, Rectum, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21039

A Pivotal Randomized, Open-Label Study Of OPTUNE(R)(TTFIELDS, 200KHZ) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma

Disease Site: Brain and Nervous System, Gliomas

View Trial Details

CLINICAL TRIAL 21084

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1PI

Disease Site: Brain and Nervous System, Gliomas

View Trial Details

CLINICAL TRIAL 21193

Pre-operative Hypofractionated Stereotactic Radiosurgery for Resectable Brain Metastases

Disease Site: Brain and Nervous System, Brain metastasis

View Trial Details

CLINICAL TRIAL 21681

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 19731

Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator Intervention for Neuro-Oncology Couples

Disease Site: Brain and Nervous System, Brain metastasis, Gliomas, Leptomeningeal (LMD), Meningiomas

View Trial Details

CLINICAL TRIAL 21737

A Pilot Study of Advanced Multi-parametric MRI to Evaluate De Novo Glioblastoma Tumors Prior to Surgical Resection

Disease Site: Brain and Nervous System, Gliomas

View Trial Details